Tissue Regenix Group PLC Directorate Change (8786T)
October 18 2017 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 8786T
Tissue Regenix Group PLC
18 October 2017
[This announcement contains inside information.]
Tissue Regenix Group plc
Directorate Change
Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc
(AIM:TRX) ("Tissue Regenix" or "The Group") today announces that
Antony Odell, Chief Executive Officer (CEO), will be stepping down
from his role and position on the Board with immediate effect. The
Board will commence a process for appointment of a new CEO. In the
interim, John Samuel, Non- Executive Chairman has assumed the role
of Executive Chairman.
John Samuel, Executive Chairman Tissue Regenix Group, commented:
"The Board of Directors and I would like to thank Antony for his
dedication and commitment to Tissue Regenix since he was appointed
CEO in 2008. He has been a key member of the executive team. During
his tenure the Company has listed on the AIM market, successfully
commercialised products in the US and earlier this year completed
the transformational acquisition of CellRight, while continuing to
pursue additional commercial opportunities. We wish him every
success in his future career."
The integration of CellRight continues as planned and current
trading remains in line with Board expectations.
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073
/ 07920
272 441
---------------------------------------- -----------
Jefferies International Ltd Tel: 020
Simon Hardy / Christopher Binks 7029 8000
---------------------------------------- -----------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan/ Rob Winder 767 1000
======================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012, Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R) , a biotech company that specializes in
regenerative medicine and is dedicated to the development of
innovative osteoinductive and wound care scaffolds that enhance
healing opportunities of defects created by trauma and disease.
CellRight's human osteobiologics may be used in spine, trauma,
general orthopedic, foot & ankle, dental, and sports medicine
surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGGGBCUUPMGMM
(END) Dow Jones Newswires
October 18, 2017 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024